132 related articles for article (PubMed ID: 34144258)
1. C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids.
Li W; Huang M; Li Y; Xia A; Tan L; Zhang Z; Wang Y; Yang J
Biochem Biophys Res Commun; 2021 Aug; 566():197-203. PubMed ID: 34144258
[TBL] [Abstract][Full Text] [Related]
2. Antitubulin activities of ansamitocins and maytansinoids.
Ikeyama S; Takeuchi M
Biochem Pharmacol; 1981 Sep; 30(17):2421-5. PubMed ID: 21043240
[TBL] [Abstract][Full Text] [Related]
3. Semisynthetic maytansine analogues for the targeted treatment of cancer.
Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
[TBL] [Abstract][Full Text] [Related]
4. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
5. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.
Goldmacher VS; Audette CA; Guan Y; Sidhom EH; Shah JV; Whiteman KR; Kovtun YV
PLoS One; 2015; 10(2):e0117523. PubMed ID: 25671541
[TBL] [Abstract][Full Text] [Related]
6. Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids.
Nittoli T; Delfino F; Kelly M; Carosso S; Markotan T; Kunz A; Chen Z; Mao S; Shan J; Navarro E; Zhao F; Makonnen S; Hickey C; Spink J; Olson W; Kirshner JR; Thurston G; Papadopoulos N
Bioorg Med Chem; 2020 Dec; 28(23):115785. PubMed ID: 33099182
[TBL] [Abstract][Full Text] [Related]
7. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Oroudjev E; Lopus M; Wilson L; Audette C; Provenzano C; Erickson H; Kovtun Y; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2700-13. PubMed ID: 20937595
[TBL] [Abstract][Full Text] [Related]
8. Maytansinol Functionalization: Towards Useful Probes for Studying Microtubule Dynamics.
Boiarska Z; Pérez-Peña H; Abel AC; Marzullo P; Álvarez-Bernad B; Bonato F; Santini B; Horvath D; Lucena-Agell D; Vasile F; Sironi M; Díaz JF; Prota AE; Pieraccini S; Passarella D
Chemistry; 2023 Jan; 29(5):e202203431. PubMed ID: 36468686
[TBL] [Abstract][Full Text] [Related]
9. Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes.
Fishkin N
Mol Pharm; 2015 Jun; 12(6):1745-51. PubMed ID: 25738231
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
11. Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.
Marzullo P; Boiarska Z; Pérez-Peña H; Abel AC; Álvarez-Bernad B; Lucena-Agell D; Vasile F; Sironi M; Altmann KH; Prota AE; Díaz JF; Pieraccini S; Passarella D
Chemistry; 2022 Jan; 28(2):e202103520. PubMed ID: 34788896
[TBL] [Abstract][Full Text] [Related]
12. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
13. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
14. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
[TBL] [Abstract][Full Text] [Related]
15. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
16. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids.
Kupchan SM; Sneden AT; Branfman AR; Howie GA; Rebhun LI; McIvor WE; Wang RW; Schnaitman TC
J Med Chem; 1978 Jan; 21(1):31-7. PubMed ID: 563462
[TBL] [Abstract][Full Text] [Related]
18. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
19. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids.
Nittoli T; Kelly MP; Delfino F; Rudge J; Kunz A; Markotan T; Spink J; Chen Z; Shan J; Navarro E; Tait M; Provoncha K; Giurleo J; Zhao F; Jiang X; Hylton D; Makonnen S; Hickey C; Kirshner JR; Thurston G; Papadopoulos N
Bioorg Med Chem; 2018 May; 26(9):2271-2279. PubMed ID: 29605304
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]